Genetic causes of dilated cardiomyopathy

Progress in Pediatric Cardiology

Volumn 37, Issue 1-2, 2014, Pages 13-18

  Mestroni, Luisa ^a   Brun, Francesca ^a,b   Spezzacatene, Anita ^a,b   Sinagra, Gianfranco ^b   Taylor, Matthew R G ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

Dilated cardiomyopathy; Gene; Heart failure; Pediatrics; Prognosis; Screening

Indexed keywords

EID: 84914158824     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2014.10.003     Document Type: Review

References (80)

1. Mestroni L., Maisch B., McKenna W.J., et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999, 20(2):93-102.
2. Hershberger R.E., Hedges D.J., Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 2013, 10(9):531-547.
3. Sugrue D.D., Rodeheffer R.J., Codd M.B., et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 1992, 117(2):117-123.
4. Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006, 296:1867-1876.
5. Codd M.B., Sugrue D.D., Gersh B.J., Melton L.J. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989, 80:564-572.
6. Rakar S., Sinagra G., Di Lenarda A., et al. Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. Eur Heart J 1997, 18:117-123.
7. Nugent A.W., Daubeney P.E., Chondros P., et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003, 348:1639-1646.
8. Lipschultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003, 348:1647-1655.
9. Cox G.F. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 2007, 24(1):15-25.
10. Cochrane A.D., Coleman D.M., Davis A.M., et al. Excellent long-term functional outcome after an operation for anomalous left coronary artery from the pulmonary artery. J Thorac Cardiovasc Surg 1999, 117:332-342.
11. Medi C., Kalman J., Haqqani H., et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia. J Am Coll Cardiol 2009, 53:1791-1797.
12. Maiya S., Sullivan I., Allgrove J., et al. Hypocalcemia and vitamin D deficiency: an important, but preventable cause of life-threatening infant heart failure. Heart 2008, 94:581-584.
13. Henry W.L., Gardin J.M., Ware J.H. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980, 62:1054-1061.
14. Mestroni L., Rocco C., Gregori D., et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol 1999, 34:181-190.
15. Hershberger R.E., Morales A., Siegfried J.D. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010, 12:655-667.
16. Bowles N.E., Bowles K.R., Towbin J.A. The "Final Common Pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000, 25:168-175.
17. Towbin J.A., Lorts A. Arrhythmias and dilated cardiomyopathy common pathogenetic pathways?. J Am Coll Cardiol 2011, 57:2169-2171.
18. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1813.
19. Kamisago M., Sharma S.D., DePalma S.R., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000, 343:1688-1696.
20. Lakdawala N.K., Funke B.H., Baxter S., et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Cardiac Fail 2012, 18:296-303.
21. Morita H., Nagai R., Seidman J.G., Seidman C.E. Sarcomere gene mutations in hypertrophy and heart failure. J Cardiovasc Transl Res 2010, 3:297-303.
22. Lakdawala N.K., Thune J.J., Colan S.D., et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet 2012, 5:503-510.
23. Mestroni L. Phenotypic heterogeneity of sarcomeric gene mutations: a matter of gain and loss?. J Am Coll Cardiol 2009, 21(54):343-345.
24. Carniel E., Taylor M.R., Sinagra G., et al. α-Myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 2005, 112:54-59.
25. Daehmlow S., Erdmann J., Knueppel T., et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun 2002, 298:116-120.
26. Weisberg A., Winegrad S. Alteration of myosin cross bridges by phosphorylation of myosin-binding-protein C in cardiac muscle. Proc Natl Acad Sci U S A 1996, 93:8999-9003.
27. Chang A.N., Potter J.D. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev 2005, 10:225-235.
28. Herman D.S., Lam L., Taylor M.R., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012, 366:619-628.
29. McNally E.M. Genetics: broken giant linked to heart failure. Nature 2012, 483(7389):281-282.
30. Merlo M., Sinagra G., Carniel E., et al. Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy. Clin Transl Sci 2013, 6:424-428.
31. Sylvius N., Tesson F. Lamin A/C and cardiac disease. Curr Opin Cardiol 2006, 21:159-165.
32. Taylor M.R., Fain P.R., Sinagra G., et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003, 41:771-780.
33. Arbustini E., Pilotto A., Repetto A., et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin a/C defect-related disease. J Am Coll Cardiol 2002, 39:981-990.
34. van Rijsingen I.A., Arbustini E., Elliott P.M., et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. J Am Coll Cardiol 2012, 59:493-500.
35. Taylor M.R., Slavov D., Gajewski A., et al. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 2005, 26:566-574.
36. McNair W.P., Ku L., Taylor M.R., et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004, 110(15):2163-2167.
37. Olson T.M., Michels V.V., Ballew J.D., et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005, 293:447-454.
38. Schmitt J.P., Kamisago M., Asahi M. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003, 299(5611):1410-1413.
39. McNair W.P., Sinagra G., Taylor M.R., et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol 2011, 57:2160-2168.
40. van Rijsingen I.A., van der Zwaag P.A., Groeneweg J.A., et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 2014, 7(4):455-465.
41. Taylor M.R., Slavov D., Ku L., et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007, 115:1244-1251.
42. Vatta M., Mohapatra B., Jimenez S., et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003, 42:2014-2027.
43. Arimura T., Hayashi T., Terada H., et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol Chem 2004, 279:6746-6752.
44. Selcen D., Engel A.G. Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann Neurol 2005, 57:269-276.
45. Towbin J.A., Hejtmancik J.F., Brink P., et al. X linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993, 87(6):1854-1865.
46. Arimura T., Ishikawa T., Nunoda S., Kawai S., Kimura A. Dilated cardiomyopathy-associated BAG3 mutations impair Z-disc assembly and enhance sensitivity to apoptosis in cardiomyocytes. Hum Mutat 2011, 32:1481-1491.
47. Norton N., Li D., Rieder M.J., et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet 2011, 88:273-282.
48. Feldman A.M., Begay R.L., Knezevic T., et al. Decreased levels of BAG3 in a family with a rare variant and in idiopathic dilated cardiomyopathy. J Cell Physiol 2014, 229(11):1697-1702.
49. Knöll R., Postel R., Wang J., et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 2007, 116:515-525.
50. Murakami T., Hayashi J.K., Noguchi S., et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006, 60:597-602.
51. Moretti M., Merlo M., Barbati G., et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail 2010, 12(9):922-927.
52. MacArthur D.G., Manolio T.A., Dimmock D.P., et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014, 508(7497):469-476.
53. Sturm A.C., Hershberger R.E. Genetic testing in cardiovascular medicine: current landscape and future horizons. Curr Opin Cardiol 2013, 28:317-325.
54. Golbus J.R., Puckelwartz M.J., Fahrenbach J.P., Dellefave-Castillo L.M., Wolfgeher D., McNally E.M. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet 2012, 5(4):391-399.
55. Fatkin D., Graham R.M. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002, 82:945-980.
56. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults - a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines - developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
57. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008, 8:933-989.
58. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
59. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
60. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100(23):2312-2318.
61. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
62. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007.
63. Packer M., Bristor M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
64. Packer M., Fowler M.B., Roecker E.B., et al. Effects of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
65. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinic outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003, 362:7-13.
66. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. Circulation 2009, 119:e391-e479.
67. Packer M., Coats A.J., Fowler M.B., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
68. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
69. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
70. Jong P., Yusuf S., Rousseau M.F., Ahn S.A., Bangdiwala S.I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003, 361:1843-1848.
71. Colucci W.S., Kolias T.J., Adams K.F., et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007, 116:49-56.
72. Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000, 2:209-212.
73. Lakdawala N.K., Winterfield J.R., Funke B.H. Arrhythmogenic disorders of genetic origin. Dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2013, 6:228-237.
74. Cirak S., Arechavala-Gomeza V., Guglieri M., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378(9791):595-605.
75. Goemans N.M., Tulinius M., van Den Akker J.T., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011, 364(16):1513-1522.
76. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357(26):2677-2686.
77. Kinali M., Arechavala-Gomeza V., Feng L., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8(10):918-928.
78. Dhandapany P.S., Razzaque M.A., Muthusami U., et al. RAF1 mutations in childhood-onset dilated cardiomyopathy. Nat Genet 2014, 46(6):635-639.
79. Choi J.C., Muchir A., Wu W., et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med 2012, 4(144):144ra102.
80. Ramos F.J., Chen S.C., Garelick M.G., et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 2012, 4(144):144ra103.